Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Long

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Lancet (London, England)|September 17, 2019
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 studyR Sharon Chinthrajah, Natasha Purington, Sandra Andorf, et al.
Frontiers in Immunology|October 10, 2018
Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food ChallengesNatasha Purington, R Sharon Chinthrajah, Andrew Long, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|August 12, 2009
Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyesCarol L Shields, Minoru Furuta, Archana Thangappan, et al.
Eclinicalmedicine|June 14, 2019
A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued <i>vs</i> Discontinued Dosing in Multifood Allergic IndividualsSandra Andorf, Natasha Purington, Divya Kumar, et al.
The Journal of Allergy and Clinical Immunology|March 5, 2023
The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disordersSayantani B Sindher, Suzanne Barshow, Jyothi Tirumalasetty, et al.
The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)Robert A Wood, R Sharon Chinthrajah, Amanda K Rudman Spergel, et al.
The Journal of Allergy and Clinical Immunology|November 4, 2019
Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?Thomas Eiwegger, Katherine Anagnostou, Stefania Arasi, et al.
The Journal of Allergy and Clinical Immunology|May 30, 2025
Introduction of allergenic foods after treatment with omalizumabJennifer Dantzer, Yamini Virkud, Julie Wang, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Lancet (London, England)|September 17, 2019
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 studyR Sharon Chinthrajah, Natasha Purington, Sandra Andorf, et al.
Frontiers in Immunology|October 10, 2018
Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food ChallengesNatasha Purington, R Sharon Chinthrajah, Andrew Long, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|August 12, 2009
Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyesCarol L Shields, Minoru Furuta, Archana Thangappan, et al.
Eclinicalmedicine|June 14, 2019
A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued <i>vs</i> Discontinued Dosing in Multifood Allergic IndividualsSandra Andorf, Natasha Purington, Divya Kumar, et al.
The Journal of Allergy and Clinical Immunology|March 5, 2023
The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disordersSayantani B Sindher, Suzanne Barshow, Jyothi Tirumalasetty, et al.
The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)Robert A Wood, R Sharon Chinthrajah, Amanda K Rudman Spergel, et al.
The Journal of Allergy and Clinical Immunology|November 4, 2019
Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?Thomas Eiwegger, Katherine Anagnostou, Stefania Arasi, et al.
The Journal of Allergy and Clinical Immunology|May 30, 2025
Introduction of allergenic foods after treatment with omalizumabJennifer Dantzer, Yamini Virkud, Julie Wang, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
Pageof 7